EUBREAST

A special thanks to all our members, supporters, patients, and friends.
wishes you a healthy and happy 2026!

🚨 NEW STUDY ALERT! 🚨

Recent data from the international ( ) study sheds critical light on the diagnostic performance of axillary ultrasound (AUS) after neoadjuvant chemotherapy (NACT) in initially node-positive breast cancer.

The article is now published in the European Journal of Cancer Elsevier.

📌 Key findings from 3,260 patients:

✅ AUS showed a specificity of 78.9%

⚠️ Sensitivity was only 46.4% - 35.7% of patients with negative AUS still had nodal disease

🧬 Diagnostic accuracy varied significantly by tumor subtype, grade, and breast response

📣 Bottom line: US alone is not reliable enough to determine surgical strategy after NACT. Axillary surgery remains essential for accurate staging in cN+ patients. HOWEVER, our findings suggest that AUS continues to play a role in guiding surgical staging in this context, provided its results are interpreted considering the tumor subtype, grade, and breast tumor response.

🔗 Read the full publication: https://doi.org/10.1016/j.ejca.2025.115607

🙏 Huge thanks to the entire study team, 288 study sites across 26 countries, and all our collaborators and sponsors.

This work was supported by AGO-B, the Claudia von Schilling Foundation, Ehmann Foundation Savognin, AWOgyn, Endomag, A Hologic Company, Merit Medical Systems, and Mammotome.

This milestone in axillary management would not be possible without your commitment!

🚨 NEW STUDY ALERT! 🚨

The international ( ) study brings new clarity to the clinical impact of lost axillary markers after neoadjuvant systemic therapy in breast cancer.

The article was recently published in the European Journal of Surgical Oncology.

📌 Key findings from 1,528 patients:
✅ Marker loss occurred in only 5.8% of cases
✅ Highest loss rate with metal clips (7.0%), none with radioactive seeds (0.0%)
✅ No significant increase in axillary recurrence observed after ~22 months average follow-up

📣 Bottom line: Marker loss is rare but highly dependent on technique and experience. Clinical decision-making must be tailored accordingly.

🔗 Read the full open-access publication: https://doi.org/10.1016/j.ejso.2025.110253

🙏 Huge thanks to the entire study team, all investigators across 288 study sites in 26 countries, and all our incredible collaborators and sponsors.

This study was supported by the AGO Breast Study Group (AGO-B), the Claudia von Schilling Foundation for Breast Cancer Research, the Ehmann Foundation Savognin, Eugen and Irmgard Hahn Foundation, Arbeitsgemeinschaft für ¨asthetische, plastische und wiederherstellende Operationsverfahren in der Gyn¨akologie e.V. (AWOgyn), EndoMag, Merit Medical, and Mammotome.

This incredible work would not be possible without your dedication!